| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| 靶点 |
VDR/vitamin D receptor; Human Endogenous Metabolite
|
||
|---|---|---|---|
| 体外研究 (In Vitro) |
骨化二醇诱导 CYP24A1 表达，EC50 为 70 nM。凝血酶表达由骨化二醇诱导，EC50 为 10-100 nM。根据共聚焦显微镜检查结果，用骨化三醇处理的细胞中的 VDR 定位模式相似，0.1-10 μM 骨化二醇以剂量依赖性方式诱导 VDR 易位到细胞核中。
|
||
| 体内研究 (In Vivo) |
三天内，将 50 ng/d 的骨化二醇或单独的载体注射到自发性高血压大鼠和正常血压 Wistar-Kyoto (WKY) 大鼠中。在对照 SHR 中，发现细胞 Ca2+ 通量和钙结合蛋白-D9K 减少。骨化二醇升高刷状缘和总细胞钙结合蛋白-D9K。另一方面，对于与 WKY 大鼠相当的血浆骨化三醇水平，在 vit-D 动物中升高的 Ca2+ 通量在 SHR 中保持较低。
|
||
| 细胞实验 |
用1,25（OH）2D3处理MCF-7细胞，检测其VDR表达、存活率和凋亡水平。鉴定CD133+MCF-7干细胞，并用VDR过表达质粒转染。测定了将MCF-7细胞存活率降低50%的他莫昔芬浓度（IC50）。还研究了Wnt/β-catenin信号传导的激活[2]。
|
||
| 动物实验 |
|
||
| 药代性质 (ADME/PK) |
Absorption, Distribution and Excretion
Readily absorbed. Metabolism / Metabolites Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3. Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3. Half Life: 288 hours Biological Half-Life 288 hours |
||
| 毒性/毒理 (Toxicokinetics/TK) |
Toxicity Summary
Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein. |
||
| 参考文献 |
|
||
| 其他信息 |
Pharmacodynamics
Calcidiol is the precursor of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. |
| 分子式 |
C27H44O2
|
|
|---|---|---|
| 分子量 |
400.64
|
|
| 精确质量 |
400.334
|
|
| 元素分析 |
C, 80.94; H, 11.07; O, 7.99
|
|
| CAS号 |
19356-17-3
|
|
| 相关CAS号 |
Calcifediol monohydrate;63283-36-3;Calcifediol-d3;140710-94-7
|
|
| PubChem CID |
5283731
|
|
| 外观&性状 |
White to off-white solid powder
|
|
| 密度 |
1.0±0.1 g/cm3
|
|
| 沸点 |
529.2±33.0 °C at 760 mmHg
|
|
| 熔点 |
74-76oC
|
|
| 闪点 |
221.4±20.0 °C
|
|
| 蒸汽压 |
0.0±3.2 mmHg at 25°C
|
|
| 折射率 |
1.536
|
|
| LogP |
7.53
|
|
| tPSA |
40.46
|
|
| 氢键供体(HBD)数目 |
2
|
|
| 氢键受体(HBA)数目 |
2
|
|
| 可旋转键数目(RBC) |
6
|
|
| 重原子数目 |
29
|
|
| 分子复杂度/Complexity |
655
|
|
| 定义原子立体中心数目 |
5
|
|
| SMILES |
O([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])[C@@]([H])(C([H])([H])[H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2([H])/C(=C(\[H])/C(/[H])=C3\C(=C([H])[H])C([H])([H])C([H])([H])[C@@]([H])(C\3([H])[H])O[H])/C([H])([H])C([H])([H])C([H])([H])[C@]12C([H])([H])[H]
|
|
| InChi Key |
JWUBBDSIWDLEOM-DTOXIADCSA-N
|
|
| InChi Code |
InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
|
|
| 化学名 |
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
|
|
| 别名 |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
|
|||
|---|---|---|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: ≥ 2.5 mg/mL (6.24 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。 *生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。 配方 2 中的溶解度: ≥ 2.08 mg/mL (5.19 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。 例如，若需制备1 mL的工作液，可将 100 μL 20.8 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。 *20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。 View More
配方 3 中的溶解度: ≥ 2.08 mg/mL (5.19 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。 配方 4 中的溶解度: 2% DMSO +30% PEG 300 +5% Tween+ddH2O: 5mg/mL 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4960 mL | 12.4800 mL | 24.9601 mL | |
| 5 mM | 0.4992 mL | 2.4960 mL | 4.9920 mL | |
| 10 mM | 0.2496 mL | 1.2480 mL | 2.4960 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;
3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;
4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。
计算结果:
工作液浓度： mg/mL；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03602261 | Active Recruiting |
Drug: Calcifediol Oral Capsule Drug: Placebo oral capsule |
Chronic Kidney Diseases Vitamin D Deficiency |
OPKO Health, Inc. | July 9, 2018 | Phase 2 |
| NCT05398939 | Recruiting | Diagnostic Test: Blood test and skin evaluation |
Acne Vulgaris Vitamin D Deficiency |
National Taiwan University Hospital |
June 6, 2022 | |
| NCT05431920 | Recruiting | Dietary Supplement: Vitamin D₃ (25-hydroxy vitamin D) |
Obesity Non-allergic Asthma |
Hospital Infantil de Mexico Federico Gomez |
October 1, 2022 | Not Applicable |
| NCT03401541 | Completed | Drug: Calcifediol Drug: Calciferol |
Vitamin D Deficiency Fat Malabsorption |
Boston University | October 1, 2018 | Early Phase 1 |
| NCT02805907 | Completed | Drug: Calcifediol Drug: Placebo |
Asthma, Bronchial | MurciaSalud | June 2016 | Phase 4 |
Pre-vitamin D3 decanoate
Butyrate-Vitamin D3
VDR agonist 2
Eldecalcitol-d6 (Eldecalcitol d6)
InvivoChem的所有产品仅用于作科学研究，不面向患者销售
Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1
COA
粤公网安备 44011102003439号